Healthcare Stock Soars On RBC Capital Outlook

Sponsored:

Tuesday, June 3, 2025

A Washington-based healthcare company is stealing the show so far during Tuesday’s session after RBC Capital maintained its Outperform rating on the stock, raising their price target to $16/share.

Seeing that this stock closed at just $2.39 yesterday, it’s no wonder that traders rushed to snatch up shares of Perspective Therapeutics, Inc. (NYSE American:CATX), pushing the small cap up to $3.48/share (+45.61%) at the early session high. This could be an indication that the stock might breakout of the multi-month consolidation it’s been stuck in. 

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.

Sponsored: